Synergy Pharmaceuticals (SGYP) Stock | Can It Go Higher?

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) Synergy Pharmaceuticals has been a hot topic in biotech recently after gaining massively toward the end of last week. However, since the gains, we’ve seen slow and steady downtrends; leading investors to ask… “Can SGYP edge up any higher?” In my opinion, the answer is yes! Not only can the … Read more

Gilead Sciences (GILD) Stock Climbs To New Highs | Can It Last?

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Science can tell what’s arguably the best success story in the biotech space. The company has produced the world’s leading treatments for both HIV and the hepatitis C virus; and investors seem to love the stock. As a matter of fact, GILD has been on a strong uptrend for … Read more

MannKind (MNKD) Stock | Why Longs Don’t Care About Declines

MannKind Corporation (NASDAQ: MNKD) If you follow my work here or elsewhere, you know that MannKind is one of my favorite stocks to follow. Aside from the debate revolving around the stock’s ability to grow, I’m intrigued by the fact that this company has come up with a way to deliver insulin to the body … Read more

Synergy Pharmaceuticals (SGYP) Stock Climbs Back Up

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) Synergy Pharmaceuticals has been the talk of the town recently. After data from a recent plecanatide study was released, the stock climbed dramatically last week. However, we saw declines Monday and Tuesday; leading investors to ask, “When will this stock pop back up?” As I mentioned in yesterday’s post, I … Read more

Gilead Sciences (GILD) Stock | Do I Smell Low Cost Opportunity?

Gilead Sciences, Inc (NASDAQ: GILD) When it comes to the biotech sector, Gilead Sciences is one of the most talked about stocks; and for good reason. It’s arguably the most interesting success story in biotech to date! The company has taken full control of both the HIV treatment market and the HCV treatment market; however, … Read more

Synergy Pharmaceuticals (SGYP) Initiates Phase 3 Testing

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) Synergy Pharmaceuticals is declining today in the market. However, there is some very positive news revolving around the stock. Today, SGYP announced that they have initiated the second of two very important phase three clinical trials aimed at evaluating the efficacy and safety of two different plecanatide treatment doses. Today, … Read more

MannKind Corporation (MNKD) Stock Should Be In Your Portfolio | Here’s Why!

MannKind Corporation (NASDAQ: MNKD) MannKind has been the talk of the town in the healthcare sector for quite some time. It’s pretty rare when a stock stays in the top ten on the healthcare heat map on Stock Twits for more than a month; but MannKind has been there for about three months now. There’s … Read more

Synergy Pharmaceuticals (SGYP) Stock Is Down…Not For Long!

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) Synergy Pharmaceuticals stock had an incredible week in the market last week. After announcing data revolving around their most recent study, the stock skyrocketed. However today, SGYP seems to be giving up some of the gains we saw last week. Nonetheless, I’m not concerned as I don’t believe these declines … Read more

Will Synergy Pharmaceuticals (SGYP) Stock Continue To Climb?

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) Synergy Pharmaceuticals has had an incredible week in the market this week. After releasing data from their most recent gastrointestinal study, the company’s stock skyrocketed. However, today, the story seems a bit different. SGYP is currently teetering on the line between profit and losses. Nonetheless, I’m not concerned. I think … Read more

TripAdvisor (TRIP) Stock Continues Climbing On Marriott Deal

TripAdvisor Inc (NASDAQ: TRIP) TripAdvisor stock is having a great day in the market today after a steep climb yesterday on a deal with Marriott. Following the deal, Deutsche Bank weighed in today; exciting investors even more. Today, we’ll talk about the deal TripAdvisor made with Marriott, what Deutsche Bank had to say, and what … Read more